Bioxyne Limited · ASX:BXN
Bioxyne — Investor Presentation (July 2025)
20 slides from Bioxyne's investor presentation, Jul 29, 2025
Slide 1: Q4 FY25
Bi=xyne Q4 FY25 y | CAMBS, = Ps MOMA —_ \ 4 } t ie . 4 : “<, j — ie ae fy rine? 3 (PHARMACEUTICAL GRADE )
Slide 2: Disclaimer
DISCLAIMER This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company). The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this presentation is subjec
Slide 3: Q4 FY25 Overview
Q4 FY25 OVERVIEW Q4 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK 3
Slide 4: Q4 FY25 Overview
Q4 FY25 OVERVIEW Q4 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK Multiple contract wins: +€3.2m Upgraded Guidance to $28.0m Doubled GMP Flower Packing Certificate of GMP compliance (A$5.8m) supply agreement revenue in FY25 and delivered Capacity to 30tn in push with Europe, Canada, Singapore
Slide 5: Financials
FINANCIALS Q4 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK 5
Slide 6: Revenue Growth
REVENUE GROWTH Record quarterly revenue of $9.5 million delivered, representing a 204% increase on Q4 FY24 & a 33% increase on Q3 FY25 Q4 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK Record quarterly revenue of $9.5 million delivered REVENUE BY QUARTER +204% PCP 204% increase on Q4 FY24 (
Slide 7: Revenue Growth
REVENUE GROWTH Revenue for the half represents a substantial increase of 33.2% increase on H1 FY25A revenue1 Q4 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK Unaudited FY25 Revenue totalled $29.3 million, REVENUE GENERATION1 representing: +214% PCP – A 214% increase on FY24 revenue of $9.3m
Slide 8: Cash Flow Positive
CASH FLOW POSITIVE The Company recorded the fourth consecutive positive cashflow period, continuing to drive consistent profitability Q4 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK Record quarterly Cash Receipts of $10.7 million, CASH RECEIPTS & NET CASH FROM OPERATING ACTIVITIES represent
Slide 9: Australian Market Growth
AUSTRALIAN MARKET GROWTH Q4 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK 9
Slide 10: Production Capacity
PRODUCTION CAPACITY Recent investment into additional equipment & facilities has underpinned a substantial increased production capability & will continue to simultaneously underpin the initial rollout of EU & UK strategy Q4 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK CURRENT AUSTRALIAN MANU
Slide 11: Australian Growth Strategy
AUSTRALIAN GROWTH STRATEGY Australian medicinal cannabis prescriptions continue to grow. BXN will continue to aggressively invest in growing domestic market share Q4 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK AUSTRALIAN MEDICINAL CANNABIS APPROVALS1 AUSTRALIAN MARKET GROWTH STRATEGY 1304k 1
Slide 12: International Growth
AUSTRALIAN MARKET GROWTH Q4 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK 12
Slide 13: EU Market Entry
EU MARKET ENTRY Czechia facility to supply rapidly growing European markets with construction beginning imminently Q4 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK BUILD MANUFACTURING & CONTROLLED TARGETING 5-10% OF GERMAN MEDICAL CANNABIS FLOWER IN FY26 PURSUE STRATEGIC ENTRIES SUSTANCE SUPPL
Slide 14: UK Market Entry
UK MARKET ENTRY The UK represents a material opportunity for the Company with the replication of the existing QLD facility set to supply a rapidly growing market with similar customer dynamics Q4 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK Q1 FY26 - ESTABLISH DISTRIBUTION CURRENT ADDRESSABLE
Slide 15: Outlook
OUTLOOK Q4 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK 15
Slide 16: Outlook
OUTLOOK Substantial growth anticipated in FY26 with multiple growth drivers underpinning revenue & margin expansion Q4 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK EUROPE UK AUS Continue to accelerate Continue to progress controlled Invest in inventory to meet controlled drugs and GMP drugs a
Slide 17: Appendix
APPENDIX 17
Slide 18: Board & Management
BOARD & MANAGEMENT Mr. Anthony Ho Samuel Watson Jason Hine Guy Robertson B. Com (UNSW), CA, FAICD, FCIS, FGIA BSc Finance and Economics BA Economics and Commerce B. Com (Hons.) CA Non-executive Chairman Managing Director Executive Director CFO & Company Secretary • Tony is an experienced company • S
Slide 19: Corporate Snapshot
CORPORATE SNAPSHOT $0.06 60m $0.04 40m $0.02 20m - - Jul-24 Aug-24 Sep-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 Apr-25 May-25 Jun-25 Volume Share Price CORPORATE SNAPSHOT (JULY-2025) MAJOR SHAREHOLDERS Shareholder Shares (m) % Shares on Issue 2,164m Breathe International Ltd 576,268,527 26.62 Op
Slide 20: Contact
CONTACT JAMES EMONSON ALPINE CAPITAL Corporate Advisor jemonson@alpinecapital.au